Lupin Pharma launches Lurasidone Hydrochloride Tablets in US

The generic equivalent of Latuda tablets has been launched in the US markets

lupin
BS Web Team New Delhi
1 min read Last Updated : Feb 21 2023 | 2:51 PM IST

Lupin Limited, a global pharmaceutical company, has announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, to market a generic equivalent of Latuda Tablets of Sunovion Pharmaceuticals, Inc. Lupin filed this update with the Bombay Stock Exchange. It issued a press release informing the public of the same.

The generic equivalent of Latuda tablets has been launched in the US markets. Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg (RLD Latuda) had estimated annual sales of $4.2 billion in the US, according to the press release.

The filing is in accordance with the requirements of Regulation 30 of the Securities and Exchange Board of India (SEBI). The company is headquartered in Mumbai, India. It has operations in the US, India, South Africa, and across the Asia Pacific, among other regions of the world.

The stock is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). At 2 pm on Tuesday, Lupin's stock was trading on the NSE for Rs 669. According to data from the Bombay Stock Exchange, Lupin has a total market capitalisation of Rs 30,476 crore.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :LupinIndian pharma companiesIndian pharmaHealth MinistryMansukh Lal MandaviyaNational Stock Exchange of India NSE

Next Story